Roivant Sciences Catapults On A 'Dream Scenario' For Its Blockbuster Hopeful

Roivant Sciences unveiled "exceptional" results Friday for its skin disease treatment, sending the biotech stock flying.

Investors Business Daily • Feb 6, 2026

Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript

Seeking Alpha • Feb 6, 2026

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

BASEL, Switzerland and LONDON and NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) and reported its financial results for the third quarter ended December 31, 2025.

GlobeNewsWire • Feb 6, 2026

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.27.

Zacks Investment Research • Feb 6, 2026

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced positive results from the Phase 2 BEACON study evaluating brepocitinib in cutaneous sarcoidosis (CS). CS is a highly morbid, chronic, and disfiguring condition with no approved therapies, and the BEACON study is the first ever industry-sponsored placebo-controlled trial in the indication to read out positively.

GlobeNewsWire • Feb 6, 2026

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that it has completed enrollment in the Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients.

GlobeNewsWire • Feb 6, 2026

Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade)

Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade)

Seeking Alpha • Feb 7, 2026

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results for the second quarter ended December 31, 2026, and provide a business update.

GlobeNewsWire • Jan 23, 2026

Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.

Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.

Seeking Alpha • Jan 13, 2026

Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript

Seeking Alpha • Jan 8, 2026